{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:32:02Z","timestamp":1790087522753,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2022R1A2B5B01001933"],"award-info":[{"award-number":["2022R1A2B5B01001933"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and objectives<\/jats:title><jats:p>As the efficacy of current diagnostic methods for myasthenia gravis (MG) remains suboptimal, there is ongoing interest in developing more effective diagnostic models. As oculomotor fatigability is one of the most common and diagnostic symptoms in MG, we aimed to investigate whether quantitative saccadic and smooth-pursuit fatigability analyses with video-oculography (VOG) are useful for diagnosis of MG.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A convenience cohort of 46 MG patients was recruited prospectively, including 35 with ocular and 11 with generalized MG (mean age, 50.9\u2009\u00b1\u200914.5\u00a0years; 17 females); 24 healthy controls (HCs) (mean age, 50.6\u2009\u00b1\u200916.3\u00a0years; 13 females) also were enrolled. Seventy-five repetitive saccades and smooth pursuits were recorded in ranges of 20\u00b0 (horizontal plane) and 15\u00b0 (vertical plane) using a three-dimensional VOG system. Based on the oculomotor range of the second saccade and smooth pursuit and the mean ranges of the last five of each, the estimated decrements (%) reflecting oculomotor fatigability were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The baseline oculomotor ranges did not show significant difference between the MG and HCs groups. However, following repetitive saccades and pursuits, the oculomotor ranges were decreased substantially during the last five cycles compared to baseline in the MG group. No such decrements were observed in the HC group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01, Mann\u2013Whitney<jats:italic>U<\/jats:italic>test). Receiver operating characteristic (ROC) analysis revealed that repetitive vertical saccades yielded the best differentiation between the MG and HC groups, with a sensitivity of 78.3% and specificity of 95.8% when using a decrement with an amplitude of 6.4% as the cutoff.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study presents an objective and reproducible method for measuring decrements of oculomotor ranges after repetitive saccadic and pursuit movements. Quantification of oculomotor fatigability using VOG could be a sensitive and specific diagnostic tool for MG and allows easy, cost-effective, accurate, and non-invasive measurements.<\/jats:p><\/jats:sec><jats:sec><jats:title>Classification of evidence<\/jats:title><jats:p>This study provides class III evidence that VOG-based quantification of saccadic and pursuit fatigability accurately identifies patients with MG.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00415-023-11611-7","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T10:03:07Z","timestamp":1677664987000},"page":"2743-2755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Oculomotor fatigability with decrements of saccade and smooth pursuit for diagnosis of myasthenia gravis"],"prefix":"10.1007","volume":"270","author":[{"given":"Thanh Tin","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ju","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hee","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunsu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-1680","authenticated-orcid":false,"given":"Sun-Young","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,1]]},"reference":[{"key":"11611_CR1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036","journal-title":"Lancet Neurol"},{"key":"11611_CR2","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"BM Conti-Fine","year":"2006","unstructured":"Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116:2843\u20132854","journal-title":"J Clin Invest"},{"key":"11611_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.nrl.0000240856.03505.b5","volume":"12","author":"LL Kusner","year":"2006","unstructured":"Kusner LL, Puwanant A, Kaminski HJ (2006) Ocular myasthenia: diagnosis, treatment, and pathogenesis. Neurologist 12:231\u2013239","journal-title":"Neurologist"},{"key":"11611_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","volume":"26","author":"L Querol","year":"2013","unstructured":"Querol L, Illa I (2013) Myasthenia gravis and the neuromuscular junction. Curr Opin Neurol 26:459\u2013465","journal-title":"Curr Opin Neurol"},{"key":"11611_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","volume":"12","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S (2016) Myasthenia gravis\u2014autoantibody characteristics and their implications for therapy. Nat Rev Neurol 12:259\u2013268","journal-title":"Nat Rev Neurol"},{"key":"11611_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1749-6632.2012.06808.x","volume":"1275","author":"JJ Plomp","year":"2012","unstructured":"Plomp JJ, Huijbers MG, van der Maarel SM, Verschuuren JJ (2012) Pathogenic IgG4 subclass autoantibodies in MuSK myasthenia gravis. Ann N Y Acad Sci 1275:114\u2013122","journal-title":"Ann N Y Acad Sci"},{"key":"11611_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11910-013-0421-9","volume":"14","author":"SH Wong","year":"2014","unstructured":"Wong SH, Huda S, Vincent A, Plant GT (2014) Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci Rep 14:1\u201310","journal-title":"Curr Neurol Neurosci Rep"},{"key":"11611_CR8","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","volume":"2","author":"A Vincent","year":"2002","unstructured":"Vincent A (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2:797\u2013804","journal-title":"Nat Rev Immunol"},{"key":"11611_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1097\/WCO.0000000000000473","volume":"30","author":"A Evoli","year":"2017","unstructured":"Evoli A (2017) Myasthenia gravis: new developments in research and treatment. Curr Opin Neurol 30:464\u2013470","journal-title":"Curr Opin Neurol"},{"key":"11611_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","volume":"48","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B (2014) Diagnostic and clinical classification of autoimmune myasthenia gravis. J Autoimmun 48:143\u2013148","journal-title":"J Autoimmun"},{"key":"11611_CR11","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","volume":"12","author":"JJ Verschuuren","year":"2013","unstructured":"Verschuuren JJ, Huijbers MG, Plomp JJ et al (2013) Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev 12:918\u2013923","journal-title":"Autoimmun Rev"},{"key":"11611_CR12","first-page":"21","volume-title":"Pathophysiology of myasthenia gravis","author":"BW Hughes","year":"2004","unstructured":"Hughes BW, De Casillas MLM, Kaminski HJ (2004) Pathophysiology of myasthenia gravis. Semin Neurol. Thieme Medical Publishers Inc, Cham, pp 21\u201330"},{"key":"11611_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/WNO.0000000000000350","volume":"36","author":"SH Wong","year":"2016","unstructured":"Wong SH, Petrie A, Plant GT (2016) Ocular myasthenia gravis: toward a risk of generalization score and sample size calculation for a randomized controlled trial of disease modification. J Neuroophthalmol 36:252\u2013258","journal-title":"J Neuroophthalmol"},{"key":"11611_CR14","doi-asserted-by":"publisher","first-page":"e25899","DOI":"10.1097\/MD.0000000000025899","volume":"100","author":"J Witthayaweerasak","year":"2021","unstructured":"Witthayaweerasak J, Rattanalert N, Aui-Aree N (2021) Prognostic factors for conversion to generalization in ocular myasthenia gravis. Medicine 100:e25899","journal-title":"Medicine"},{"key":"11611_CR15","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","volume":"505","author":"D Grob","year":"1987","unstructured":"Grob D, Arsura EL, Brunner NG, Namba T (1987) The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci 505:472\u2013499","journal-title":"Ann N Y Acad Sci"},{"key":"11611_CR16","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S1388-2457(00)00307-2","volume":"111","author":"L Padua","year":"2000","unstructured":"Padua L, Stalberg E, LoMonaco M, Evoli A, Batocchi A, Tonali P (2000) SFEMG in ocular myasthenia gravis diagnosis. Clin Neurophysiol 111:1203\u20131207","journal-title":"Clin Neurophysiol"},{"key":"11611_CR17","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.293.15.1906","volume":"293","author":"K Scherer","year":"2005","unstructured":"Scherer K, Bedlack RS, Simel DL (2005) Does this patient have myasthenia gravis? JAMA 293:1906\u20131914","journal-title":"JAMA"},{"key":"11611_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00415-019-09631-3","volume":"267","author":"MP Giannoccaro","year":"2020","unstructured":"Giannoccaro MP, Di Stasi V, Zanesini C, Donadio V, Avoni P, Liguori R (2020) Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation. J Neurol 267:739\u2013745","journal-title":"J Neurol"},{"key":"11611_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ncl.2018.01.010","volume":"36","author":"M Pasnoor","year":"2018","unstructured":"Pasnoor M, Dimachkie MM, Farmakidis C, Barohn RJ (2018) Diagnosis of myasthenia gravis. Neurol Clin 36:261\u2013274","journal-title":"Neurol Clin"},{"key":"11611_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","volume":"16","author":"M Benatar","year":"2006","unstructured":"Benatar M (2006) A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 16:459\u2013467","journal-title":"Neuromuscul Disord"},{"key":"11611_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00127893-200109000-00004","volume":"7","author":"MS Okun","year":"2001","unstructured":"Okun MS, Charriez CM, Bhatti MT, Watson RT, Swift T (2001) Tensilon and the diagnosis of myasthenia gravis: are we using the Tensilon test too much? Neurologist 7:295\u2013299","journal-title":"Neurologist"},{"key":"11611_CR22","doi-asserted-by":"publisher","first-page":"e1693","DOI":"10.1212\/WNL.0000000000009306","volume":"94","author":"RH de Meel","year":"2020","unstructured":"de Meel RH, Keene KR, Wirth MA et al (2020) Repetitive ocular vestibular evoked myogenic potentials in myasthenia gravis. Neurology 94:e1693\u2013e1701","journal-title":"Neurology"},{"key":"11611_CR23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1212\/WNL.0000000000002383","volume":"86","author":"Y Valko","year":"2016","unstructured":"Valko Y, Rosengren SM, Jung HH, Straumann D, Landau K, Weber KP (2016) Ocular vestibular evoked myogenic potentials as a test for myasthenia gravis. Neurology 86:660\u2013668","journal-title":"Neurology"},{"key":"11611_CR24","first-page":"54","volume":"18","author":"J-H Chae","year":"2019","unstructured":"Chae J-H, Shin H-J, Shin B-S, Seo M-W, Oh S-Y (2019) Two cases of myasthenia gravis showing fatigibility presenting with decreased gain of smooth pursuit. J Korean Balance Soc 18:54\u201358","journal-title":"J Korean Balance Soc"},{"key":"11611_CR25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4103\/0028-3886.336330","volume":"70","author":"T Sirin","year":"2022","unstructured":"Sirin T, Karaaslan Z, Arkali B et al (2022) Is video-oculography a predictive test for myasthenia gravis with ocular symptoms? Neurol India 70:80\u201386","journal-title":"Neurol India"},{"key":"11611_CR26","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1097\/WNO.0000000000001438","volume":"42","author":"C Murray","year":"2022","unstructured":"Murray C, Newsham D, Rowe F, Noonan C, Marsh IB (2022) The use of the saccadometer to identify saccadic characteristics in myasthenia gravis: a pilot study. J Neuroophthalmol 42:e267\u2013e273","journal-title":"J Neuroophthalmol"},{"key":"11611_CR27","first-page":"61","volume-title":"Handbook of clinical neurology","author":"T Haslwanter","year":"2010","unstructured":"Haslwanter T, Clarke AH (2010) Eye movement measurement: electro-oculography and video-oculography. Handbook of clinical neurology. Elsevier, pp 61\u201379"},{"key":"11611_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/BF02335779","volume":"12","author":"G Tedeschi","year":"1991","unstructured":"Tedeschi G, Di Costanzo A, Allocca S et al (1991) Saccadic eye movements analysis in the early diagnosis of myasthenia gravis. Ital J Neurol Sci 12:389\u2013395","journal-title":"Ital J Neurol Sci"},{"key":"11611_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-10986-3","author":"K Yoganathan","year":"2022","unstructured":"Yoganathan K, Stevenson A, Tahir A, Sadler R, Radunovic A, Malek N (2022) Bedside and laboratory diagnostic testing in myasthenia. J Neurol. https:\/\/doi.org\/10.1007\/s00415-022-10986-3","journal-title":"J Neurol"},{"key":"11611_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780195324266.001.0001","volume-title":"Eye movement disorders","author":"A Wong","year":"2008","unstructured":"Wong A (2008) Eye movement disorders. Oxford University Press"},{"key":"11611_CR31","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1249\/MSS.0000000000001307","volume":"49","author":"CJ Connell","year":"2017","unstructured":"Connell CJ, Thompson B, Turuwhenua J, Srzich A, Gant N (2017) Effects of dopamine and norepinephrine on exercise-induced oculomotor fatigue. Med Sci Sports Exerc 49:1778\u20131788","journal-title":"Med Sci Sports Exerc"},{"key":"11611_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep42726","volume":"7","author":"CJ Connell","year":"2017","unstructured":"Connell CJ, Thompson B, Turuwhenua J, Srzich A, Gant N (2017) Fatigue-related impairments in oculomotor control are prevented by norepinephrine-dopamine reuptake inhibition. Sci Rep 7:1\u201312","journal-title":"Sci Rep"},{"key":"11611_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00213-010-1906-8","volume":"212","author":"DJ Roche","year":"2010","unstructured":"Roche DJ, King AC (2010) Alcohol impairment of saccadic and smooth pursuit eye movements: impact of risk factors for alcohol dependence. Psychopharmacology 212:33\u201344","journal-title":"Psychopharmacology"},{"key":"11611_CR34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1152\/jappl.1949.2.5.247","volume":"2","author":"J Bro\u017dek","year":"1949","unstructured":"Bro\u017dek J (1949) Quantitative criteria of oculomotor performance and fatigue. J Appl Physiol 2:247\u2013260","journal-title":"J Appl Physiol"},{"key":"11611_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0014-4886(75)90225-3","volume":"48","author":"AT Bahill","year":"1975","unstructured":"Bahill AT, Stark L (1975) Overlapping saccades and glissades are produced by fatigue in the saccadic eye movement system. Exp Neurol 48:95\u2013106","journal-title":"Exp Neurol"},{"key":"11611_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3233\/JND-190407","volume":"6","author":"RH de Meel","year":"2019","unstructured":"de Meel RH, Raadsheer WF, van Zwet EW, Tannemaat MR, Verschuuren JJ (2019) Ocular weakness in myasthenia gravis: changes in affected muscles are a distinct clinical feature. J Neuromuscul Dis 6:369\u2013376","journal-title":"J Neuromuscul Dis"},{"key":"11611_CR37","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s00415-008-0843-5","volume":"255","author":"T Sander","year":"2008","unstructured":"Sander T, Sprenger A, Machner B, Rambold H, Helmchen C (2008) Disjunctive saccadesduring smooth pursuit eye movements in ocular myasthenia gravis. J Neurol 255:1094","journal-title":"J Neurol"},{"key":"11611_CR38","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1001\/archopht.1976.03910040003001","volume":"94","author":"DG Cogan","year":"1976","unstructured":"Cogan DG, Yee RD, Gittinger J (1976) Rapid eye movements in myasthenia gravis: I. Clinical observations. Arch Ophthalmol 94:1083\u20131085","journal-title":"Arch Ophthalmol"},{"key":"11611_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1749-6632.2012.06841.x","volume":"1275","author":"A Serra","year":"2012","unstructured":"Serra A, Ruff RL, Leigh RJ (2012) Neuromuscular transmission failure in myasthenia gravis: decrement of safety factor and susceptibility of extraocular muscles. Ann N Y Acad Sci 1275:129\u2013135","journal-title":"Ann N Y Acad Sci"},{"key":"11611_CR40","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/ptj\/81.11.1810","volume":"81","author":"W Scott","year":"2001","unstructured":"Scott W, Stevens J, Binder-Macleod SA (2001) Human skeletal muscle fiber type classifications. Phys Ther 81:1810\u20131816","journal-title":"Phys Ther"},{"key":"11611_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0079-6123(05)51002-1","volume":"151","author":"RF Spencer","year":"2006","unstructured":"Spencer RF, Porter JD (2006) Biological organization of the extraocular muscles. Prog Brain Res 151:43\u201380","journal-title":"Prog Brain Res"},{"key":"11611_CR42","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/archopht.1976.03910040299001","volume":"94","author":"RD Yee","year":"1976","unstructured":"Yee RD, Cogan DG, Zee DS, Baloh RW, Honrubia V (1976) Rapid eye movements in myasthenia gravis: II. Electro-oculographic analysis. Arch Ophthalmol 94:1465\u20131472","journal-title":"Arch Ophthalmol"},{"key":"11611_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/15569520701830992","volume":"16","author":"M Cleary","year":"2008","unstructured":"Cleary M, Williams GJ, Metcalfe RA (2008) The pattern of extra-ocular muscle involvement in ocular myasthenia. Strabismus 16:11\u201318","journal-title":"Strabismus"},{"key":"11611_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jocn.2015.08.026","volume":"25","author":"Y Almog","year":"2016","unstructured":"Almog Y, Ben-David M, Nemet AY (2016) Inferior oblique muscle paresis as a sign of myasthenia gravis. J Clin Neurosci 25:50\u201353","journal-title":"J Clin Neurosci"},{"key":"11611_CR45","first-page":"4317","volume":"35","author":"JR Lukas","year":"1994","unstructured":"Lukas JR, Aigner M, Blumer R, Heinzl H, Mayr R (1994) Number and distribution of neuromuscular spindles in human extraocular muscles. Invest Ophthalmol Vis Sci 35:4317\u20134327","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"11611_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s004170050370","volume":"238","author":"S Tian","year":"2000","unstructured":"Tian S, Nishida Y, Isberg B, Lennerstrand G (2000) MRI measurements of normal extraocular muscles and other orbital structures. Graefes Arch Clin Exp Ophthalmol 238:393\u2013404","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"11611_CR47","doi-asserted-by":"publisher","first-page":"083","DOI":"10.1055\/s-2003-40755","volume":"23","author":"RM Pascuzzi","year":"2003","unstructured":"Pascuzzi RM (2003) The edrophonium test. Semin Neurol 23:083\u2013088","journal-title":"Semin Neurol"},{"key":"11611_CR48","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ICU.0000000000000526","volume":"29","author":"E Fortin","year":"2018","unstructured":"Fortin E, Cestari DM, Weinberg DH (2018) Ocular myasthenia gravis: an update on diagnosis and treatment. Curr Opin Ophthalmol 29:477\u2013484","journal-title":"Curr Opin Ophthalmol"},{"key":"11611_CR49","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/mus.20030","volume":"29","author":"JC Keesey","year":"2004","unstructured":"Keesey JC (2004) Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29:484\u2013505","journal-title":"Muscle Nerve"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11611-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11611-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11611-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T13:07:15Z","timestamp":1728997635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11611-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["11611"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11611-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,1]]},"assertion":[{"value":"26 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance of ethical standard statement"}}]}}